lung carcinoma a549 Search Results


weight genomic dna  (ATCC)
94
ATCC weight genomic dna
Weight Genomic Dna, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/weight genomic dna/product/ATCC
Average 94 stars, based on 1 article reviews
weight genomic dna - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
human lung carcinoma immortalized cell line  (TaKaRa)
93
TaKaRa human lung carcinoma immortalized cell line
Human Lung Carcinoma Immortalized Cell Line, supplied by TaKaRa, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human lung carcinoma immortalized cell line/product/TaKaRa
Average 93 stars, based on 1 article reviews
human lung carcinoma immortalized cell line - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
a549 human non-small-cell lung carcinoma cells  (Pharmaseed Ltd)
90
Pharmaseed Ltd a549 human non-small-cell lung carcinoma cells
A549 Human Non Small Cell Lung Carcinoma Cells, supplied by Pharmaseed Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a549 human non-small-cell lung carcinoma cells/product/Pharmaseed Ltd
Average 90 stars, based on 1 article reviews
a549 human non-small-cell lung carcinoma cells - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
human lung carcinoma cell line a549  (Flow Laboratories)
90
Flow Laboratories human lung carcinoma cell line a549
Human Lung Carcinoma Cell Line A549, supplied by Flow Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human lung carcinoma cell line a549/product/Flow Laboratories
Average 90 stars, based on 1 article reviews
human lung carcinoma cell line a549 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
human lung carcinoma cell line a-549  (Chinou Jouhou Shisutemu)
90
Chinou Jouhou Shisutemu human lung carcinoma cell line a-549
Human Lung Carcinoma Cell Line A 549, supplied by Chinou Jouhou Shisutemu, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human lung carcinoma cell line a-549/product/Chinou Jouhou Shisutemu
Average 90 stars, based on 1 article reviews
human lung carcinoma cell line a-549 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
lung alveolar epithelial cells a549  (Cedarlane)
90
Cedarlane lung alveolar epithelial cells a549
a , Configuration of AngioPlate that allocates three inlet wells and two outlet wells for each terminal lung alveoli model. b , Design of the vascularized alveoli terminal with alveolar duct and sac and the resulting network perfused with FITC microparticles (1 µm, green) and TRITC microparticles (1 µm, red) for visualization. Scale bar, 1 mm. c , Vascularized alveoli terminal seeded with GFP-HUVECs (green) and alveolar <t>epithelial</t> cells <t>(A549)</t> on day 7. Scale bar, 1mm. d-e , Image and quantification of alveolar epithelium thickening over time. f-g , Fluorescent images of the cross-section of the vascularized alveolar sac stained for F-actin (red) and DAPI (blue). h , Histology cross-section of an vascularized terminal alveoli stained with Masson’s trichrome, E-Cadherin and CD-31. scale bar, 100 µm. i , A frame of a video that shows the physical expansion of the alveoli terminal actuated by a ventilator. j-k , Vector map and quantification that show the physical expansion of an alveolar sac at different levels of ventilation pressure. Statistical significance was determined using one-way ANOVA with the Holm-Sidak method. *P≤0.05 **P≤0.01 ***P ≤0.001
Lung Alveolar Epithelial Cells A549, supplied by Cedarlane, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lung alveolar epithelial cells a549/product/Cedarlane
Average 90 stars, based on 1 article reviews
lung alveolar epithelial cells a549 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
human lung carcinoma a549 cell line  (Sinovac BioTech)
90
Sinovac BioTech human lung carcinoma a549 cell line
a , Configuration of AngioPlate that allocates three inlet wells and two outlet wells for each terminal lung alveoli model. b , Design of the vascularized alveoli terminal with alveolar duct and sac and the resulting network perfused with FITC microparticles (1 µm, green) and TRITC microparticles (1 µm, red) for visualization. Scale bar, 1 mm. c , Vascularized alveoli terminal seeded with GFP-HUVECs (green) and alveolar <t>epithelial</t> cells <t>(A549)</t> on day 7. Scale bar, 1mm. d-e , Image and quantification of alveolar epithelium thickening over time. f-g , Fluorescent images of the cross-section of the vascularized alveolar sac stained for F-actin (red) and DAPI (blue). h , Histology cross-section of an vascularized terminal alveoli stained with Masson’s trichrome, E-Cadherin and CD-31. scale bar, 100 µm. i , A frame of a video that shows the physical expansion of the alveoli terminal actuated by a ventilator. j-k , Vector map and quantification that show the physical expansion of an alveolar sac at different levels of ventilation pressure. Statistical significance was determined using one-way ANOVA with the Holm-Sidak method. *P≤0.05 **P≤0.01 ***P ≤0.001
Human Lung Carcinoma A549 Cell Line, supplied by Sinovac BioTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human lung carcinoma a549 cell line/product/Sinovac BioTech
Average 90 stars, based on 1 article reviews
human lung carcinoma a549 cell line - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
engineered human lung carcinoma cell line a549 expressing cd19  (Novoprotein)
90
Novoprotein engineered human lung carcinoma cell line a549 expressing cd19
a , Configuration of AngioPlate that allocates three inlet wells and two outlet wells for each terminal lung alveoli model. b , Design of the vascularized alveoli terminal with alveolar duct and sac and the resulting network perfused with FITC microparticles (1 µm, green) and TRITC microparticles (1 µm, red) for visualization. Scale bar, 1 mm. c , Vascularized alveoli terminal seeded with GFP-HUVECs (green) and alveolar <t>epithelial</t> cells <t>(A549)</t> on day 7. Scale bar, 1mm. d-e , Image and quantification of alveolar epithelium thickening over time. f-g , Fluorescent images of the cross-section of the vascularized alveolar sac stained for F-actin (red) and DAPI (blue). h , Histology cross-section of an vascularized terminal alveoli stained with Masson’s trichrome, E-Cadherin and CD-31. scale bar, 100 µm. i , A frame of a video that shows the physical expansion of the alveoli terminal actuated by a ventilator. j-k , Vector map and quantification that show the physical expansion of an alveolar sac at different levels of ventilation pressure. Statistical significance was determined using one-way ANOVA with the Holm-Sidak method. *P≤0.05 **P≤0.01 ***P ≤0.001
Engineered Human Lung Carcinoma Cell Line A549 Expressing Cd19, supplied by Novoprotein, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/engineered human lung carcinoma cell line a549 expressing cd19/product/Novoprotein
Average 90 stars, based on 1 article reviews
engineered human lung carcinoma cell line a549 expressing cd19 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
lung carcinoma a549  (Kamar Products Inc)
90
Kamar Products Inc lung carcinoma a549
a , Configuration of AngioPlate that allocates three inlet wells and two outlet wells for each terminal lung alveoli model. b , Design of the vascularized alveoli terminal with alveolar duct and sac and the resulting network perfused with FITC microparticles (1 µm, green) and TRITC microparticles (1 µm, red) for visualization. Scale bar, 1 mm. c , Vascularized alveoli terminal seeded with GFP-HUVECs (green) and alveolar <t>epithelial</t> cells <t>(A549)</t> on day 7. Scale bar, 1mm. d-e , Image and quantification of alveolar epithelium thickening over time. f-g , Fluorescent images of the cross-section of the vascularized alveolar sac stained for F-actin (red) and DAPI (blue). h , Histology cross-section of an vascularized terminal alveoli stained with Masson’s trichrome, E-Cadherin and CD-31. scale bar, 100 µm. i , A frame of a video that shows the physical expansion of the alveoli terminal actuated by a ventilator. j-k , Vector map and quantification that show the physical expansion of an alveolar sac at different levels of ventilation pressure. Statistical significance was determined using one-way ANOVA with the Holm-Sidak method. *P≤0.05 **P≤0.01 ***P ≤0.001
Lung Carcinoma A549, supplied by Kamar Products Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lung carcinoma a549/product/Kamar Products Inc
Average 90 stars, based on 1 article reviews
lung carcinoma a549 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
lung carcinoma a549 cell growth  (Shanghai Pudong Development Bank Co Ltd)
90
Shanghai Pudong Development Bank Co Ltd lung carcinoma a549 cell growth
a , Configuration of AngioPlate that allocates three inlet wells and two outlet wells for each terminal lung alveoli model. b , Design of the vascularized alveoli terminal with alveolar duct and sac and the resulting network perfused with FITC microparticles (1 µm, green) and TRITC microparticles (1 µm, red) for visualization. Scale bar, 1 mm. c , Vascularized alveoli terminal seeded with GFP-HUVECs (green) and alveolar <t>epithelial</t> cells <t>(A549)</t> on day 7. Scale bar, 1mm. d-e , Image and quantification of alveolar epithelium thickening over time. f-g , Fluorescent images of the cross-section of the vascularized alveolar sac stained for F-actin (red) and DAPI (blue). h , Histology cross-section of an vascularized terminal alveoli stained with Masson’s trichrome, E-Cadherin and CD-31. scale bar, 100 µm. i , A frame of a video that shows the physical expansion of the alveoli terminal actuated by a ventilator. j-k , Vector map and quantification that show the physical expansion of an alveolar sac at different levels of ventilation pressure. Statistical significance was determined using one-way ANOVA with the Holm-Sidak method. *P≤0.05 **P≤0.01 ***P ≤0.001
Lung Carcinoma A549 Cell Growth, supplied by Shanghai Pudong Development Bank Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lung carcinoma a549 cell growth/product/Shanghai Pudong Development Bank Co Ltd
Average 90 stars, based on 1 article reviews
lung carcinoma a549 cell growth - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
a549 cells  (Purdue University Cytometry)
90
Purdue University Cytometry a549 cells
Cytotoxicity and lytic ability of piggyBac-NK2GD.CAR-NK cells against CD73 + targets. a Mean fluorescence intensity (MFI) of intracellular IFN-γ production by both NK-92 and piggyBac-NKG2D.CAR-NK-92 cells. b Degranulation as measured via CD107a expression (MFI) by both NK-92 and piggyBac-NKG2D.CAR-NK-92 cells. c Lytic activity of NK-92 and piggyBac-NKG2D.CAR-NK-92 cells against CD73 + GBM43, GBM10, <t>A549</t> or PC3 cells, respectively. Data are presented as the mean ± SEM ( n = 4). * P < 0.05, ** P < 0.01
A549 Cells, supplied by Purdue University Cytometry, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a549 cells/product/Purdue University Cytometry
Average 90 stars, based on 1 article reviews
a549 cells - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
a549 cell  (Kuang Lung Shing)
90
Kuang Lung Shing a549 cell
Downstream target sites of Pyk2 in human cancers. Pyk2 increases the activation of some downstream targets to reinforce human cancer progression and invasion
A549 Cell, supplied by Kuang Lung Shing, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a549 cell/product/Kuang Lung Shing
Average 90 stars, based on 1 article reviews
a549 cell - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


a , Configuration of AngioPlate that allocates three inlet wells and two outlet wells for each terminal lung alveoli model. b , Design of the vascularized alveoli terminal with alveolar duct and sac and the resulting network perfused with FITC microparticles (1 µm, green) and TRITC microparticles (1 µm, red) for visualization. Scale bar, 1 mm. c , Vascularized alveoli terminal seeded with GFP-HUVECs (green) and alveolar epithelial cells (A549) on day 7. Scale bar, 1mm. d-e , Image and quantification of alveolar epithelium thickening over time. f-g , Fluorescent images of the cross-section of the vascularized alveolar sac stained for F-actin (red) and DAPI (blue). h , Histology cross-section of an vascularized terminal alveoli stained with Masson’s trichrome, E-Cadherin and CD-31. scale bar, 100 µm. i , A frame of a video that shows the physical expansion of the alveoli terminal actuated by a ventilator. j-k , Vector map and quantification that show the physical expansion of an alveolar sac at different levels of ventilation pressure. Statistical significance was determined using one-way ANOVA with the Holm-Sidak method. *P≤0.05 **P≤0.01 ***P ≤0.001

Journal: bioRxiv

Article Title: AngioPlate – Biofabrication of perfusable complex tissues in multi-well plates with 4D subtractive manufacturing

doi: 10.1101/2021.08.13.456244

Figure Lengend Snippet: a , Configuration of AngioPlate that allocates three inlet wells and two outlet wells for each terminal lung alveoli model. b , Design of the vascularized alveoli terminal with alveolar duct and sac and the resulting network perfused with FITC microparticles (1 µm, green) and TRITC microparticles (1 µm, red) for visualization. Scale bar, 1 mm. c , Vascularized alveoli terminal seeded with GFP-HUVECs (green) and alveolar epithelial cells (A549) on day 7. Scale bar, 1mm. d-e , Image and quantification of alveolar epithelium thickening over time. f-g , Fluorescent images of the cross-section of the vascularized alveolar sac stained for F-actin (red) and DAPI (blue). h , Histology cross-section of an vascularized terminal alveoli stained with Masson’s trichrome, E-Cadherin and CD-31. scale bar, 100 µm. i , A frame of a video that shows the physical expansion of the alveoli terminal actuated by a ventilator. j-k , Vector map and quantification that show the physical expansion of an alveolar sac at different levels of ventilation pressure. Statistical significance was determined using one-way ANOVA with the Holm-Sidak method. *P≤0.05 **P≤0.01 ***P ≤0.001

Article Snippet: Renal Proximal Tubule Epithelial Cells (RPTEC-TERT1, Everycyte, Cat# CHT-003-0002) and Lung Alveolar Epithelial Cells (A549, Cedarlane Labs, Cat# PTA-6231) were cultured as per manufacturer’s instructions.

Techniques: Staining, Plasmid Preparation

Cytotoxicity and lytic ability of piggyBac-NK2GD.CAR-NK cells against CD73 + targets. a Mean fluorescence intensity (MFI) of intracellular IFN-γ production by both NK-92 and piggyBac-NKG2D.CAR-NK-92 cells. b Degranulation as measured via CD107a expression (MFI) by both NK-92 and piggyBac-NKG2D.CAR-NK-92 cells. c Lytic activity of NK-92 and piggyBac-NKG2D.CAR-NK-92 cells against CD73 + GBM43, GBM10, A549 or PC3 cells, respectively. Data are presented as the mean ± SEM ( n = 4). * P < 0.05, ** P < 0.01

Journal: Journal for Immunotherapy of Cancer

Article Title: Purinergic targeting enhances immunotherapy of CD73 + solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells

doi: 10.1186/s40425-018-0441-8

Figure Lengend Snippet: Cytotoxicity and lytic ability of piggyBac-NK2GD.CAR-NK cells against CD73 + targets. a Mean fluorescence intensity (MFI) of intracellular IFN-γ production by both NK-92 and piggyBac-NKG2D.CAR-NK-92 cells. b Degranulation as measured via CD107a expression (MFI) by both NK-92 and piggyBac-NKG2D.CAR-NK-92 cells. c Lytic activity of NK-92 and piggyBac-NKG2D.CAR-NK-92 cells against CD73 + GBM43, GBM10, A549 or PC3 cells, respectively. Data are presented as the mean ± SEM ( n = 4). * P < 0.05, ** P < 0.01

Article Snippet: A549 cells (kindly provided by Dr. Darci Trader, Purdue University) were grown in DMEM supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin.

Techniques: Fluorescence, Expressing, Activity Assay

Targeting CD73 improves cytolytic activity of piggyBac-NKG2D.CAR-NK cells. CD73 expression levels on ( a ) GBM43, ( b ) GBM10, ( c ) A549, and ( d ) PC3 cell lines, respectively. Lytic activity of piggyBac-NKG2D.CAR-NK-92 cells against ( e ) GBM43, ( f ) GBM10, ( g ) A549 or ( h ) PC3 cells, in the presence of anti-CD73 antibody and adenosine deaminase inhibitor (ADAi) EHNA (30 μM), respectively. Data are presented as the mean ± SEM ( n = 4). * P < 0.05, ** P < 0.01

Journal: Journal for Immunotherapy of Cancer

Article Title: Purinergic targeting enhances immunotherapy of CD73 + solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells

doi: 10.1186/s40425-018-0441-8

Figure Lengend Snippet: Targeting CD73 improves cytolytic activity of piggyBac-NKG2D.CAR-NK cells. CD73 expression levels on ( a ) GBM43, ( b ) GBM10, ( c ) A549, and ( d ) PC3 cell lines, respectively. Lytic activity of piggyBac-NKG2D.CAR-NK-92 cells against ( e ) GBM43, ( f ) GBM10, ( g ) A549 or ( h ) PC3 cells, in the presence of anti-CD73 antibody and adenosine deaminase inhibitor (ADAi) EHNA (30 μM), respectively. Data are presented as the mean ± SEM ( n = 4). * P < 0.05, ** P < 0.01

Article Snippet: A549 cells (kindly provided by Dr. Darci Trader, Purdue University) were grown in DMEM supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin.

Techniques: Activity Assay, Expressing

Downstream target sites of Pyk2 in human cancers. Pyk2 increases the activation of some downstream targets to reinforce human cancer progression and invasion

Journal: Cell Biology International

Article Title: EGFR signaling pathway occupies an important position in cancer‐related downstream signaling pathways of Pyk2

doi: 10.1002/cbin.11209

Figure Lengend Snippet: Downstream target sites of Pyk2 in human cancers. Pyk2 increases the activation of some downstream targets to reinforce human cancer progression and invasion

Article Snippet: ALDH1a1 , Lung cancer , A549 cell, H460 cell , Enhancing cancer cell colony formation , Kuang et al. ( ) .

Techniques: Activation Assay, Migration